MCQ Questions
🔍 Search
Menu

Biotechnology and Medical Technology Practice — MCQs with Answers (Set 7)

Practise 25 questions on Biotechnology and Medical Technology.

0 / 25 correct · click an option to check it

Q1. On which date was the Ministry of AYUSH created?

Show answer and explanation

Answer: D

The department was upgraded into the full Ministry of AYUSH on 9 November 2014.

Q2. On what date was the Ministry of AYUSH created by upgrading it from a department?

Show answer and explanation

Answer: A

The answer is 9 November 2014. The Department of AYUSH became a full Ministry on that date. Memory hook: AYUSH became a ministry in 2014.

Q3. On which date was the Ministry of Earth Sciences (MoES) established?

Show answer and explanation

Answer: B

MoES was established on 29 January 2006, merging meteorological bodies with the Department of Ocean Development.

Q4. What form of cooperation did the Ministry of Ayush offer the Ministry of Defence, to help expand Ayush services in military hospitals?

Show answer and explanation

Answer: B

The Ministry of Ayush offered technical support, professional guidance, and institutional cooperation, including signing an MoU, to help implement Ayush services in military hospitals.

Q5. As of December 2025, how many health facilities nationwide had AYUSH services co-located?

Show answer and explanation

Answer: D

13,249 health facilities had AYUSH co-location as of December 2025 — 6,302 PHCs, 3,191 CHCs, 475 District Hospitals, and other facilities.

Q6. The Ayush Vertical, under the Directorate General of Health Services, has published Standard Treatment Guidelines covering how many musculoskeletal disorders?

Show answer and explanation

Answer: B

The Ayush Vertical under DGHS has published Standard Treatment Guidelines for 6 common musculoskeletal disorders and 5 common metabolic disorders, supporting clinical integration of Ayush into mainstream healthcare.

Q7. Which global health body has named antimicrobial resistance one of the top public health threats?

Show answer and explanation

Answer: A

The World Health Organization has named antimicrobial resistance one of the top global public health threats.

Q8. In the July 2026 reshuffle, Archana Varma was named Secretary of which department?

Show answer and explanation

Answer: A

Archana Varma was named Secretary, Department of Official Language, Ministry of Home Affairs.

Q9. Per the 28 July 2026 Parliament reply, what was India’s Ayush product export figure for FY2025-26?

Show answer and explanation

Answer: B

Ayush product exports reached $1,251.25 million in FY2025-26, up from $869.81 million in FY2020-21 — a CAGR of 7.54%.

Q10. The AOGUSY scheme, reviewed in the 24 July 2026 Parliament reply, has what total budget outlay?

Show answer and explanation

Answer: D

AOGUSY has run since 2021-22 with a Rs 122 crore budget over five years.

Q11. Under the RDI Fund, reviewed in a 23 July 2026 Parliament reply, how much has TDB (Technology Development Board) approved in project support so far?

Show answer and explanation

Answer: C

TDB has approved 22 projects with a total project cost of Rs 4,744 crore, including RDI Fund support of Rs 2,192 crore.

Q12. Since adopting a Multi-Model Ensemble approach in 2021 for long-range monsoon forecasting, IMD’s average absolute forecast error has been what share of the Long Period Average, per a 29 July 2026 Parliament reply?

Show answer and explanation

Answer: B

Since 2021, IMD’s operational monsoon forecasts have stayed within error limits, averaging just 2.2% of the LPA over 2021-2025.

Q13. The Ministry of Ayush signed an MoU with IndiaAI (MeitY) in July 2026. Which platform will the Ministry onboard to share eligible health research artefacts?

Show answer and explanation

Answer: A

The Ministry will onboard AIKosh to share datasets, AI models, and toolkits, and gain subsidised access to GPU-based and high-performance computing infrastructure through IndiaAI.

Q14. On 7 August 2026, BIS signed an MoU with CCRAS to set global Ayurveda quality standards. What made this MoU notable for BIS?

Show answer and explanation

Answer: D

This was BIS’s 100th MoU overall, and its first with an AYUSH organisation, aimed at globally benchmarked Ayurveda standards.

Q15. With which Ayush body did BIS sign its first MoU on 7 August 2026?

Show answer and explanation

Answer: C

BIS signed with CCRAS to set globally benchmarked standards for Ayurvedic products.

Q16. As of the 4 August 2026 Parliament update, roughly how much has the National Ayush Mission released to States and UTs for Ayush infrastructure, from 2014-15 to 2025-26?

Show answer and explanation

Answer: C

About Rs 6,407 crore was released to States and UTs under the National Ayush Mission, for Ayush infrastructure, from 2014-15 to 2025-26.

Q17. Per the NSSO’s 79th Round survey (2022-23), what share of urban India reported awareness of Ayush systems?

Show answer and explanation

Answer: D

The NSSO’s 79th Round found 96% Ayush awareness in urban India, and 94.8% in rural India; usage within the past year stood at 52.9% urban and 46.3% rural.

Q18. Which group supplied the largest share of GenomeIndia samples?

Show answer and explanation

Answer: B

PIB’s Lok Sabha reply gives about 36.7% rural, 32.2% urban and 31.1% tribal. The shares are close, but rural is the largest.

Q19. Beyond the base sensor, the research team demonstrated a self-powered version. How does it generate its own power?

Show answer and explanation

Answer: C

The researchers integrated the sensor with a flexible piezoelectric nanogenerator, which harvests mechanical energy from simple human motions and converts it into electrical power, enabling gas detection without an external power source.

Q20. How does comparing tumour and healthy tissue transcriptomes help cancer research?

Show answer and explanation

Answer: A

Comparing tumour and healthy tissue transcriptomes helps identify which genes drive a specific cancer’s growth, informing targeted treatment research.

Q21. On which date did the Union Cabinet approve Phase-III of the Biomedical Research Career Programme?

Show answer and explanation

Answer: D

The correct answer is 1 October 2025. The Cabinet approved Phase-III on that date. The 15 July 2026 option is wrong because that is when Dr Jitendra Singh launched the phase. The 24 August 2024 option is wrong because that is when the Cabinet approved the BioE3 Policy. The 1 April 2025 option is wrong because no source gives it. Memory hook: approved October 2025, launched July 2026.

Q22. Consider the following statements about India’s drug and device safety programmes: 1. The Materiovigilance Programme of India (MvPI) monitors the safety of medicines. 2. The Pharmacovigilance Programme of India (PvPI) was operationalised in July 2010. 3. IPC has been the National Coordination Centre of MvPI since 2018. Which of the statements given above is/are correct?

Show answer and explanation

Answer: D

The correct answer is 2 and 3 only. Statement 2 is right: PvPI began in July 2010. Statement 3 is right: IPC has been the MvPI coordination centre since 2018.

Statement 1 is wrong. MvPI watches medical devices, not medicines. PvPI is the medicines programme. So every option with statement 1 fails.

Memory hook: Pharma for medicines, materio for devices.

Q23. SYNCHN, THSTI’s industry meet, was held for the third time in 2026. In which year was the first meet held?

Show answer and explanation

Answer: B

The correct answer is 2024. The first SYNCHN was in July 2024. The second was in July 2025, and the third on 15 July 2026.

2025 was the second meet. 2026 was the third. No SYNCHN was held in 2023.

Memory hook: SYNCHN: 2024, 2025, 2026.

Q24. The UK regulator MHRA authorised the first medicine that uses CRISPR on 16 November 2023. What is it called?

Show answer and explanation

Answer: C

The MHRA authorised Casgevy on 16 November 2023. It was the first medicine licensed that uses CRISPR. It edits the BCL11A enhancer to raise fetal haemoglobin.

Q25. The first CRISPR-based therapy to gain regulatory approval, Casgevy, was approved by the UK’s MHRA in November 2023 and the US FDA in December 2023, to treat which disease?

Show answer and explanation

Answer: C

Casgevy treats sickle cell disease, and later transfusion-dependent beta-thalassemia. It edits a patient’s own blood stem cells to prevent the sickling of red blood cells.

Beyond the answer

    Share your thoughts

    ✨Ask doubt
    ✨ Ask a Question AI×

    MCQ Question is an independent study site, not affiliated with any government body or exam authority. Official sources: UPSC upsc.gov.in · SSC ssc.gov.in · NCERT ncert.nic.in · PIB pib.gov.in

    WhatsApp support: +91 9319788829